Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9707061 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25366224 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL15369081 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL13983301 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25365258 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25366902 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25365949 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24268977 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL10177866 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL11498283 | 0.98 | ALDH1A1 (0.46) | ALDH1A1MAPTHPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707315-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | Beijing Mapu New Materials Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| EP-3452536-B1 | SELF-COOLING FOAM-CONTAINING COMPOSITE MATERIALS | BASF SE (DE) | 2024-01-17 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| CN-114609824-A | Polarizing film with adhesive layer | 日东电工株式会社 | 2022-06-10 | — | — | CN | claimed |
| US-11248151-B2 | Self-cooling foam-containing composite materials | BASF SE (DE) | 2022-02-15 | — | — | US | claimed |
| US-20200216733-A9 | SELF-COOLING FOAM-CONTAINING COMPOSITE MATERIALS | BASF SE (DE) | 2020-07-09 | — | — | US | claimed |
| EP-3452427-B1 | SELF-COOLING COMPOSITE MATERIALS | BASF SE (DE) | 2020-03-04 | — | — | EP | claimed |
| US-20190144338-A1 | SELF-COOLING COMPOSITE MATERIALS | BASF SE (DE) | 2019-05-16 | — | — | US | claimed |
| US-20190119541-A1 | SELF-COOLING FOAM-CONTAINING COMPOSITE MATERIALS | BASF SE (DE) | 2019-04-25 | — | — | US | claimed |
| EP-4707315-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | Beijing Mapu New Materials Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024245366-A1 | COPOLYMER, COMPOSITION AND USE THEREOF | 北京马普新材料有限公司 | 2024-12-05 | — | — | WO | disclosed |
| CN-1134717-A | Heat-reversible thickenable binder composition | SANYO CHEMICAL IND LTD (JP) | 1996-10-30 | — | — | CN | disclosed |
| EP-0190685-B1 | HETEROCYCLIC AMIDES | G.D. Searle & Co. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4981853-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS | G. D. SEARLE & CO. (US) | 1991-01-01 | — | — | US | disclosed |
| US-4959364-A | Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides | G. D. SEARLE & CO. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0190685-A2 | Heterocyclic amides | G.D. Searle & Co. (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | ALDH1A1 2154/4885MAPT 238/4885HPGD 1073/4885 |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | ALDH1A1 2068/4885MAPT 256/4885HPGD 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.